TRANSASIA BIO-MEDICALS LTD. COMMITTED TO A HEALTHIER AND HAPPIER WORLD
COMMITTED TO A HEALTHIER AND HAPPIER WORLD
The beginnings
Transasia Bio-Medicals Ltd. was started by Mr. Suresh Vazirani, a qualified electrical engineer, who was moved by the lacunae that existed in the Indian healthcare industry. Way back in the 1979, in India there was a dearth of good quality medical devices. And the imported ones that were available often broke down. To make matters worse, after-sales service was a major challenge. This prompted, this young gentleman to shoulder the responsibility of meeting the needs of the medical fraternity for quality and affordable diagnostic solutions. With a measly sum of Rs. 250 and a Rs. 1 lakh loan from a good Samaritan friend, Mr. Suresh Vazirani started Transasia Bio-Medicals Ltd., a provider of after-sales support for imported equipment.
Standing the test of time
But, it was not as simple. At that time, most labs functioned without any automated equipment and required a lot of manual testing, leaving scope for errors. For three years, Mr. Vazirani put in relentless efforts to convince pathologists on the benefits of automated blood analyzers. However, these equipment were imported and not suited to the highly fragmented, price-sensitive markets in India with its poor infrastructure and expertise. And this paved the path for setting up of Transasia’s manufacturing facility to provide Made in India, high quality equipment for affordable and accessible diagnostics.
Reaching out to the world
Transasia soon started expanding its reach not just in India, but also globally. It was among the first Indian IVD Companies to receive a CE and US FDA certification for its products, thus opening the gates for its entry into the European markets. Mr. Vazirani soon setup Erba Mannheim, Germany and combined efficient, low-cost manufacturing and unparalleled market expertise to make world-class European technology accessible to emerging markets.
Making in India for the World
Transasia has been endorsing the ‘Make in India’ concept since the early 1990s, long before it formally came into prominence. Its state-of-the-art manufacturing facilities in Mumbai, Daman, Baddi, Sikkim and Vizag are ISO, ICMED and US FDA-compliant and employ GMP. Transasia is also the first IVD Company in India to be awarded the ZED Diamond Quality rating from the Ministry of MSME, Govt. of India and the Quality Council of India for its exports-oriented manufacturing facility at Mumbai.
R&D forms the core of Transasia’s long-term growth strategy. At its R&D centres of excellence in France, Austria, UK, India, Czech Republic and USA, the company constantly innovates to always be ahead in the game. Transasia-Erba products are arduously tested and validated in the most extreme condition to ensure uncompromising performance for its users.
Transasia offers more than 1000 instruments and test kits to cater to communicable and lifestyle diseases across all segments- Blood Banking, Clinical Chemistry, Critical Care, Coagulation, Diabetes Management, ESR, Hematology, Immunology, Microbiology, Urinalysis and Molecular Diagnostics.
Going strong as India’s Leading IVD Company
For over four decades, Transasia has been at the forefront of high quality diagnostic solutions. Transasia is proud to have the largest team of 400+ sales and 350+ service specialists in the Indian IVD Industry, 350+ distributors and 25 zonal offices, to reach out to over 5000+ Tier II–IV cities, towns and villages, including the farthest northeastern regions in a record time of just 4–5 hours.
Numbers speak for us!
Today, Transasia has an impressive installed base of 70,000 equipment across 40,000 laboratories in India. Over 150 crore blood tests are done on a Transasia equipment every year, benefitting more than 200 million people. In fact, every second, 50 tests are conducted on a Transasia product!
Globally, The Transasia-Erba group serves millions in over 100 countries through its 15 overseas subsidiaries in USA, France, Germany, Poland, Czech Republic, Turkey, Russia, UK, Vietnam, Austria, Brazil and UAE. It continues to grow to increase the number of lives it touches in its vision of being ‘Committed to a Healthier and Happier World’.
Recognition galore
All along its journey, Transasia has gained reputation and immense respect for its commitment to healthcare. Among its numerous accolades, the company has been bestowed with ‘The Economic Times Best Brand 2019’, ‘Brand of the Decade’, ‘Best Company in Medical Devices – IVD’ by Medgate Today magazine and ‘Export Company of the Year - Indian Medical Devices’ by the Government of India. At the World Economic Forum in 2014, Transasia was conferred the ‘Global Growth Company Award’.
In fact, Mr. Vazirani is also the proud recipient of the 'Niryat Shree' Gold trophy by the Hon'ble President of India, for two years for exceling in the field of exports. He has also been felicitated by Dr. Harsh Vardhan, Hon’ble Minister of Science & Technology, Govt. of India as the ‘Pioneer for Make in India Concept’ initiative in 2015.
Shaping the future of the Indian IVD industry
The COVID-19 pandemic brought to the forefront the need for quality diagnostic infrastructure as the first step to contain the spread of infection. For Transasia, more than ever before the focus is now on preventive diagnostics.
Through cohesive collaboration between domain experts in India and abroad, the Transasia-Erba Group has introduced COVID testing kits of high sensitivity and specificity in molecular and ELISA formats. Going forward, there will be a need for Indian manufacturers to scale up production. The setting up of
Transasia’s world-class manufacturing facility at AMTZ, Vishakhapatnam, is an answer to this foresight. The facility is the first of its kind and largest in Asia for COVID-19 products. In the future, this facility will serve as the global hub for all infectious tests such as TB, Malaria, HIV, Hepatitis etc.
Additionally, Transasia has already announced the setting up of its sixth manufacturing facility at Medtech Park in Telangana. This facility will be dedicated to cater to biochemistry, hematology, immunology and molecular tests important for prevention of lifestyle diseases such as cardiac and diabetes as well as dengue and TB tests for domestic and export markets. The company is also looking at doubling its R&D spend and accelerating its long-term growth to drive revenue synergies and efficiencies.
Between now and 2023, Transasia’s R&D labs in France, UK, US, Austria and India will launch over 10 exciting, state of-the-art instruments in the fields of CLIA, molecular, high-end hematology, artificial intelligence and LIS, among others. Also in the offing is a “Total Lab Automation” solution aimed at mid- and large size laboratories. All these will soon make Erba-Transasia among the top-five companies globally to have ‘Total solutions in Laboratory Diagnostics. Providing end-to-end services with an emphasis on training will continue to remain most relevant to Transasia, as the need for knowledge and competencies continues to increase.